Man Group’s Sana Biotechnology SANA Stock Holding History

Man Group’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-29,800	Closed	-$122K	–	2259
2023 Q4	$122K	Buy	+29,800	New	+$110K	﹤0.01%	1966

Other funds holding SANA

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Man Group's SANA Position: Q1 2024 in Review

Man Group sold out of Sana Biotechnology (SANA) in Q1 2024, closing a stake of 29,800 shares — an estimated $122K sold.

Man Group first reported a position in SANA in Q4 2023 and held it in 1 quarter. The position peaked at $122K in Q4 2023. 154 funds tracked by Wall St. Rank hold SANA as of Q1 2024.

Man Group reported no remaining Sana Biotechnology position as of Q1 2024 after selling out during the quarter.
Man Group sold 29,800 Sana Biotechnology shares in Q1 2024, an estimated $122K.
Man Group first reported a position in Sana Biotechnology in Q4 2023 and held it in 1 quarter.
Man Group's Sana Biotechnology position peaked at $122K in Q4 2023.
154 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.